| Document |
Document Title |
|
WO/2020/102326A1 |
The present application provides methods for determining the level of NAD in a patient, including a whole blood sample from a patient. In addition, methods of increasing NAD levels in combination with determining the NAD level in a patie...
|
|
WO/2020/085720A1 |
The present invention relates to a process for simultaneously preparing a lactic acid bacteria nucleotide and a low-molecular weight functional biomaterial having utility in industries related to skincare and cosmetics, and more specific...
|
|
WO/2020/086366A1 |
The present disclosure provides methods for separating nucleic acids in a sample based on the length of the nucleic acids using a capillary electrophoresis device with formamide as a denaturing agent and a non-aqueous separation matrix c...
|
|
WO/2020/086834A1 |
Disclosed herein, inter alia, are compounds, compositions, and methods of using the same for the sequencing of a nucleic acid.
|
|
WO/2020/078807A1 |
The present invention relates to a prodrug compound of the general formula I or II. The prodrug compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3...
|
|
WO/2020/078808A1 |
The present invention relates to a compound of the general formula I or II. The compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in ...
|
|
WO/2020/081690A1 |
A compound has the following formula (I) or formula (II), an isomer thereof, a tautomer thereof, a pharmaceutical acceptable solvate thereof, or a pharmaceutical acceptable prodrug thereof.
|
|
WO/2020/078000A1 |
1,3-disubstituted-2H-imidazolyl-2-carbene is a common type of azacyclocarbene, which may be used in a plurality of fields, comprising catalyzing organic reactions, acting as a transition metal ligand, and acting as a supporting ligand in...
|
|
WO/2020/073274A1 |
Provided is a method for determining the sequence of a target single-chain polynucleotide, which method comprises monitoring the successive incorporation of nucleotides complementary to the target single-chain polynucleotide, wherein the...
|
|
WO/2020/074004A1 |
Provided are a compound of formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, uses of said compoung acting as a STING agonist.
|
|
WO/2020/072497A1 |
The invention provides a compound of formula (I): (I) wherein R is methyl or ethyl. The invention also provides a process for the preparation of the compound. The invention further provides a method for increasing cell NAD+ production or...
|
|
WO/2020/073026A1 |
This disclosure provides a method of synthesis of 4'-thioribose NAD+ and analogues thereof, using an efficient chemoenzymatic approach. Also provided are methods of inhibiting the CD38 enzyme and compounds including 4'-thioribose NAD+ an...
|
|
WO/2020/068657A1 |
Halogenated analogs of 5-aza-2'-deoxycytidine, such as halogenated analogs of 5-aza-4'-thio-2'-deoxycytidine (5-aza-T-dCyd) are described. Pharmaceutical compositions including a halogenated analog and methods of using the halogenated an...
|
|
WO/2020/069424A1 |
The present disclosure provides methods of sequencing polynucleotides and compounds, compositions useful for sequencing of polynucleotides. The chemical compounds include nucleotides and their analogs which possess a sugar moiety compris...
|
|
WO/2020/056713A1 |
A method for preparing high-purity NAD, comprising: adjusting a pH value to 6.0-8.0, removing insoluble substances, heating to 35 ± 1°C, adding ethanol, cooling to 6 ± 0.5°C, crystallizing, filtering, heating a filtrate to 25-30°C, ...
|
|
WO/2020/057546A1 |
A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following...
|
|
WO/2020/054444A1 |
[Problem] To develop a technique that can stabilize the higher-order structure of a nucleic acid and can be used in analysis of nucleic acid structure. [Solution] This guanosine derivative compound is represented by formula 1. In the for...
|
|
WO/2020/055753A1 |
The post-translational modification (PTM) and signaling molecule poly(ADP-ribose) (PAR) has an impact on diverse biological processes. PTM is regulated by a series of ADP-ribosyl glycohydrolases (PARG enzymes) that cleave polymers and/or...
|
|
WO/2020/051686A1 |
CD73 (also known as ecto-5 ' -nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune...
|
|
WO/2020/050411A1 |
The present invention provides a method for producing a glycoside compound represented by general formula (3), said glycoside compound enabling the synthesis of a desired compound (an amidite) with high purity. This method comprises a st...
|
|
WO/2020/045628A1 |
The present invention addresses the problem of providing a nucleic acid analog, and a pharmaceutical composition, an anti-hepatitis virus agent and a preventive or therapeutic agent for a hepatitis virus-related disease each comprising a...
|
|
WO/2020/047082A1 |
This application discloses CD73 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents fo...
|
|
WO/2020/042729A1 |
Disclosed are a 6-disulfide-substituted-2'-deoxyguanosine compound and a preparation method therefor and a use thereof in an anti-tumor drug. Using 2'-deoxyguanosine as a structure mother nucleus, the present invention designs and synthe...
|
|
WO/2020/041051A1 |
Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.
|
|
WO/2020/041050A1 |
Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.
|
|
WO/2020/037275A1 |
Disclosed is a compound of formula (I), wherein Q, U, T, A, a, b, c, and n are as defined herein. Also disclosed are methods of inhibiting ecto‑5'‑nucleotidase, inhibiting suppression of an antitumor immune response, inhibiting tumor...
|
|
WO/2020/036199A1 |
The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-3
4,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,2
0,22,25,27-decaaza-34λ5,39λ5-diphosphaoctacyclo[28.6.4.13,
36.128,31.0...
|
|
WO/2020/032152A1 |
Current synthesis methods for 4'-substituted nucleoside derivatives include a step in which stereoisomers are produced and therefore have problems such as decreased yield and complication of a refinement step. Thus, a synthesis method ha...
|
|
WO/2020/033624A1 |
The present disclosure is directed to methods of treating a disease associated with pathogenic B cells comprising administering to a subject in need thereof an effective amount of an Adora2A (adenosine A2A receptor) agonist. The method m...
|
|
WO/2020/031131A1 |
The invention relates to compounds of Formulae (I), (Ia), (II) and (IIa), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
|
|
WO/2020/029647A1 |
Provided in the present invention is a method for synthesizing a nucleoside compound and an intermediate thereof, wherein the method is carried out by introducing a protective group at position 6 of guanine ketocarbonyl, causing only 9 N...
|
|
WO/2020/028682A1 |
The present invention relates to amino acid salts of nicotinic acid and nicotinamide and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: (I) wherein A, L, M1, M2,...
|
|
WO/2020/026054A1 |
The compositions and compounds of formula I and formula II which includes nucleic acid synthesis inhibitor conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as ph...
|
|
WO/2020/020208A1 |
The present application relates to a method for preparing trifluridine, comprising reacting a compound of formula III with a compound of formula IV in a first solvent in the presence of an acid to obtain a compound of formula II, and per...
|
|
WO/2020/017085A1 |
The present invention pertains to: an alkoxyphenyl derivative with which oligonucleotides can by synthesized by a liquid-phase synthesis method easier and faster than conventional methods; a nucleoside protector and a nucleotide protecto...
|
|
WO/2020/013712A1 |
Inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use as therapeutic agents against various cancers. The invention relates to compounds, pharmaceutical...
|
|
WO/2020/010560A1 |
Disclosed in the present invention are phosphoramidite compounds, a preparation method therefor, and use thereof. The present invention provides phosphoramidite compounds represented by formula (1), wherein R is (I) or (II) and X is hydr...
|
|
WO/2020/012332A1 |
Molecule having the structural formula (I): (I) for use as targeting probe of translating ribosomes and ribosome-interacting proteins.
|
|
WO/2020/007070A1 |
The present invention discloses a crystal form, a preparation method and an application of a 4'-substituted nucleoside compound I having the following structure, including salts, prodrugs, and compositions thereof. Animal pharmacokinetic...
|
|
WO/2020/002469A1 |
The present invention relates to new reagents and methods for modifying nucleic acids where an azide-containing nucleoside or nucleotide derivative is applied to living cells followed by a nitrogenous derivative of dibenzo-1,5-cyclooctad...
|
|
WO/2020/001475A1 |
This invention relates to phosphorus-containing prodrugs of gemcitabine and their use in the treatment of cancer and viral infectious diseases. Compared with the parent drug (i.e., Gemcitabine), the prodrugs of present invention show a s...
|
|
WO/2020/006157A1 |
Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety that is a binder of a target protein DOT1L to induce degradation of...
|
|
WO/2019/246289A1 |
Methods, devices, reagents and kits designed to improve the performance of proteomic based assays are provided. Such methods have a wide utility in proteomic applications for research and development, diagnostics and therapeutics by prov...
|
|
WO/2019/246403A1 |
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
|
|
WO/2019/237297A1 |
An improved process for preparing the compound (I) is provided: which may be used in the synthesis of e.g. AL-335; AL-355 is a nucleoside inhibitor of NS3B polymerase, which plays an important role in the replication of the hepatitis C v...
|
|
WO/2019/236777A1 |
The invention provides methods of monitoring development of renal inflammation in a subject following administration of a nephrotoxic agent. The methods involve analyzing levels of one or more UDP-hexoses, such as UDP-glucose, UDP-galact...
|
|
WO/2019/227526A1 |
Provided is a fluorescently labelled nucleotide having a structure represented by formula I. The fluorescently labelled nucleotide is linked by a covalent bond between deoxyribonucleoside triphosphate and a fluorescent dye molecule and i...
|
|
WO/2019/228319A1 |
The present invention belongs to the field of medical technology and relates to an intestinal MCT1 carrier protein design-based prodrug and a preparation method therefor, and in particular relates to a preparation method for a short-chai...
|
|
WO/2019/226952A1 |
An oligo- or polynucleotide analogue having one or more structures of the general formula: where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is used for treating obesity-related metabolic diseases.
|
|
WO/2019/226755A1 |
The present invention relates to amino acid salts of nicotinic acid ribosides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein M1, R1, R2, and R3 are a...
|
